A.G. Waks

机构：Dana-Farber Cancer Institute

发表论文 14 篇 · 总被引 135 次 · h-index 4

代表论文

• Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer (2023 · Annals of Oncology · 被引 56)
• HER2DX genomic test in early-stage HER2-positive breast cancer (2024 · ESMO Open · 被引 33)
• Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer (2024 · ESMO Open · 被引 28)
• HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers (2025 · ESMO Open · 被引 8)
• Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study (2025 · ESMO Open · 被引 4)
• Assessment of the HER2DX Assay in Patients with ERBB2 -Positive Breast Cancer Treated with Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab (2024 · UNC Libraries · 被引 3)